Ichnos Glenmark Innovation subsidiary IGI Therapeutics has signed an exclusive licensing agreement with AbbVie for ISB 2001, ...

AbbVie has placed a high price on that potential, coughing up $700 million for a phase 1 candidate and offering up to $1.225 ...

About APVO455: Advancing Nectin-4 T-cell Targeting in Solid Tumors APVO455 is a preclinical Nectin-4 x CD3 bispecific T-cell engager designed for tumors such as bladder, breast, NSCLC, and head and ...

The deal hands AbbVie a drug that’s shown early promise in multiple myeloma and may be useful treating other cancers and ...

During early drug development and preclinical development, researchers use in vitro cultured lymphocytes to induce cytokine ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...

Aptevo Expands Differentiated CD3 Portfolio with APVO455, Advancing a Suite of Targeted T-cell Engagers Provided by ACCESS Newswire Jun 20, 2025, 5:55:00 AM ...

According to Regeneron, the drug is a bispecific antibody that binds to B-cell maturation antigen (BCMA) on cancerous plasma cells and CD3 on T cells, directing the immune system to attack and destroy ...

Aptevo Expands Differentiated CD3 Portfolio with APVO455, Advancing a Suite of Targeted T-cell Engagers ACCESS Newswire - Fri Jun 20, 3:55AM CDT ...

Preclinical data support a novel combination of MB-101 (IL13Ra2-targeted CAR-T cell therapy) and MB-108 (HSV-1 oncolytic virus) to optimize clinical results FDA previously granted Orphan Drug ...

This approval comes almost a year after the drug received a complete response letter due to third-party manufacturing issues.

Explore how the ratio of pd-1+ treg to ctl and the presence of tertiary lymphoid structures can influence treatment outcomes ...